



PRIVATE FUNDING OPPORTUNITIES: DEC 22, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

1. ADDF/NIH Request for Proposals, Alzheimer's Drug Discovery Foundation (ADDF)

The ADDF considers financial assistance for relevant grant applications that were submitted to the National Institute on Aging (NIA) or the National Institute of Neurological Disorders and Stroke (NINDS) and were scored but not funded. Proposals that fall within the ADDF's current funding priorities for drug discovery, clinical trials, biomarkers, and prevention will be considered.

The ADDF will accept eligible applications on a rolling basis and will provide an expedited review, minimizing time and effort on the part of the investigator(s). To expedite the application process, eligible investigators may submit their NIA or NINDS applications and a copy of the study section review directly to the ADDF. In addition, NIA and NINDS staff will identify eligible investigators whose applications in response to the below-listed FOAs were scored but unfunded, and will notify them of this opportunity thrice yearly in conjunction with Institute funding decisions. The ADDF will attempt to support parts or all of applications that fall within the foundation's mission and funding priorities.

Receiving interim funding by the ADDF will enable investigators to continue valuable research projects and obtain additional preliminary data to aid in future funding efforts.

Award Amount: Unspecified

Indirect Costs: Unspecified

LOI Deadline: Continuous

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/nih>



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.

2. Biomarkers Development, Alzheimer's Drug Discovery Foundation (ADDF)

This Request for Proposals (RFP) seeks to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease and related dementias. This includes companion biomarkers for specific clinical-stage therapies and biomarkers with broader applicability across trials and therapeutic targets.

FUNDING PRIORITIES

Neuroimaging: Positron emission tomography (PET) ligands for target engagement and pharmacodynamic measurements of novel and repurposed therapeutics, and novel magnetic resonance imaging (MRI) methods to measure structural, blood flow, and white matter changes in the brain

Cerebrospinal fluid (CSF) and blood-based biomarkers: Multiplex ELISA or mass spectrometry of specific target(s) or transcriptomics, proteomics, metabolomics, or lipidomics signatures

Functional activity measures: Electroencephalogram (EEG), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS)

Award Amount: \$150,000-\$300,000 paid over 1-2 years

Indirect Costs: None

LOI Deadline: Jan 19, 2018

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers>

3. Beyond the Pipeline, Alzheimer's Drug Discovery Foundation (ADDF)

The ADDF seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

FUNDING PRIORITIES

Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods, supplements, and drugs. However, high-powered studies are needed--ideally with dose, duration, and responder profiles--in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. More information here.

Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond

the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology.

Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding drug discovery programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

Award Amount:

- \$50,000-\$100,000 for 1 year for epidemiological analyses based on scope of research
- Up to \$3 million paid over multiple years based on stage and scope of research.

Indirect Costs: None

LOI Deadline: Jan 19, 2018

Website: <http://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline>

4. Drug Discovery, Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer's disease, related dementias, and cognitive aging by supporting promising therapeutic approaches. The ADDF's Drug Discovery Request for Proposals (RFP) focuses on supporting programs that aim to:

1. Advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or
2. Build preclinical evidence in relevant animal models for repurposed/repositioned drugs or natural products

Award Amount: \$150,000-\$600,000 for 1 year

Indirect Costs: None

LOI Deadline: Jan 19, 2018

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-discovery>

5. Program to Accelerate Clinical Trials (PACT), Alzheimer's Drug Discovery Foundation (ADDF)

The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. This program will fund (1) clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); (2) proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; (3) regulatory studies for investigational new drug (IND)/clinical trial application (CTA) preclinical packages that are required before testing novel drugs in human subjects.

Award Amount: Up to \$3 million

Indirect Costs: None

LOI Deadline: Jan 19, 2018

Website: <http://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact>

6. Clinical Trial Grants, FRAXA Research Foundation

Each year, FRAXA funds medical research aimed at finding specific treatments and ultimately a cure for fragile X syndrome. Our goal is to bring practical treatment into current medical practice as quickly as possible; so preference is given to projects that have a clear practical application and the results of which will be shared in a timely fashion.

These grants are strictly for clinical research with fragile X subjects. Strong emphasis will be placed on clinical trials of potentially disease-modifying agents which have been previously validated in fragile X animal models. Other types of clinical research may be considered, such as biomarker studies in fragile X patients, or trials of symptomatic therapies; however, these will be accorded lower priority in funding decisions. Budgets and grant structure are flexible but may be subject to some negotiation.

Clinical trial grants:

- Flexible in amount and duration.
- Must involve human subjects with fragile X.
- Highest priority is given to clinical trials of potentially disease-modifying therapeutics which have previously been validated in fragile X animal models.
- No limit to structure of grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or time-frame (though all grants over one year still need yearly renewal)

Award Amount: Unspecified

Indirect Costs: Unspecified

LOI Deadline: Continuous

Website: <https://www.fraxa.org/fragile-x-research-funding-opportunities/>

7. General Research Grant, Friedreich's Ataxia Research Alliance (FARA)

FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for FA.

FARA's Grant Program Priorities:

1. Advance understanding of neuroscience / neuro systems - understanding the neurodegeneration of FA and implications for therapies
2. Advance drug discovery
 - Highest priority in this category will be given to genetic, epigenetic and protein approaches that target increasing frataxin levels
3. Facilitate the drug development process and translational research so that the most promising discoveries are rapidly brought to treatment trials
 - Highest priority in this category will be given to IND-enabling studies, biomarker discovery and validation, early phase or pilot clinical studies
4. Advance clinical research - natural history, discovery and validation of clinical outcome measures and/or biomarkers, identification of early (including pre-symptomatic) quantifiable clinical features, patient reported outcomes, investigator-initiated clinical trials, or evidence-based clinical treatment guidelines
 - Highest priority in this category will be given to clinical research that utilizes or expands resources of the Collaborative Clinical Research Network in FA
5. Reduce the morbidity and mortality caused by cardiac disease in FA

Award Amount: \$150,000-\$300,000 paid over 1-2 years

Indirect Costs: None

LOI Deadline: Feb 1, 2018

Website: <http://www.curefa.org/grant.html>

8. Walter A. Rosenblith New Investigator Award, Health Effects Institute (HEI)

HEI's New Investigator Award provides funding for outstanding investigators who are beginning independent research. By providing financial support for investigators at this point in their careers, HEI hopes to encourage highly qualified individuals to undertake research on the health effects of air pollution.

Since the early 1980s, HEI's research program has addressed a broad range of questions about the health effects of air pollutants derived from motor vehicle emissions, including carbon monoxide, nitrogen oxides, ozone, particulate matter -- including diesel particles and associated compounds -- methanol, and air toxics. Several studies have addressed the effects of exposure to more than one pollutant. Research projects are often interdisciplinary in nature and span a range of scientific fields, including atmospheric science, epidemiology, exposure science, statistics, and toxicology. In considering potential research topics, applicants should be aware of

HEI's current areas of interest, as described in the HEI Strategic Plan for the Health Effects of Air Pollution 2015-2020. The plan focuses on four key areas: (1) addressing challenges of multi-pollutant science, (2) improving science for decisions: accountability and transparency, (3) addressing emerging fuels and technologies, and (4) addressing global health science.

HEI studies have used a wide range of designs: modeling, methods development, experiments with cell cultures, animal studies, controlled human exposure studies, and epidemiologic investigations. In all studies, accurate characterization of exposure and appropriate statistical analyses are important. HEI's ultimate goal is to provide scientific evidence that can be used in regulatory decisions or provide better information for risk assessment; thus, human studies and studies to improve extrapolation from animals to humans are an important part of HEI's program. In addition, there are several crosscutting issues that the HEI Research Committee would like to emphasize in HEI-funded studies: development, application, and testing of multipollutant statistical models and methods; identification and integration of at-risk populations into HEI studies; enhanced exposure assessment; consideration of climate change and health; application of new biologic techniques in air pollution health research; evaluation of other health outcomes and modifying factors; and capacity building, particularly support of early-career investigators.

HEI encourages investigators to submit applications addressing these high priority research areas. However, HEI realizes that other areas of research may lead to results important to its mission. For this reason, HEI will also consider particularly innovative or high quality applications in other areas that are relevant to the overall goals of HEI's program.

Award Amount: \$450,000 paid over 3 years

Indirect Costs: 30%

Pre-Application Deadline: Feb 7, 2018

Website: <https://www.healtheffects.org/research/funding/rfa/17-3-walter-rosenblith-new-investigator-award>

9. Fellowship Awards, Jane Coffin Childs Memorial Fund for Medical Research (JCC Fund)

The Fund was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The Fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers.

Award Amount: \$165,300 paid over 3 years, which includes \$1000 for each dependent child

Indirect Costs: None

Application Deadline: Feb 1, 2018

Website: <http://www.jccfund.org/fellowship-information/>

10. Research Grants, National Pancreas Foundation (NPF)

The National Pancreas Foundation (NPF) is a private, non-profit organization established to support the funding of research related to pancreatic diseases. It also provides support for the men, women, and children who are suffering from diseases of the pancreas.

The research must be in the field of pancreatic diseases. Studies intended to advance knowledge in the areas of pancreatic carcinoma, and all forms of pancreatitis would be the closest to the areas of interest of the NPF. Studies more closely related to diabetes will not be accepted.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: Jan 31, 2018

Website: <http://pancreasfoundation.org/research/grants-and-awards/>

11. Innovator Awards for Neuroscience Research, New York Stem Cell Foundation (NYSCF)

NYSCF is soliciting applications from early career investigators for Innovator awards in neuroscience. The goal of this initiative is to foster truly bold, innovative scientists with the potential to transform the field of neuroscience. Applicants are encouraged in the fundamental areas of developmental, cellular, cognitive, and translational neuroscience, broadly interpreted. Applicants need not be working in areas related to stem cells.

Award Amount: \$1.5 million paid over 5 years

Indirect Costs: Unspecified

Application Deadline: Feb 21, 2018

Website: <https://nyscf.org/programs/extramural-grants/applicants/neuroscience-investigator-awards/>

12. Innovator Awards for Stem Cell Research, New York Stem Cell Foundation (NYSCF)

NYSCF is soliciting applications from early career investigators for Innovator Awards to be used for exploring the basic biology and translational potential of stem cells. The goal of this initiative is to foster bold and innovative scientists with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. In addition to providing funding, NYSCF partners with investigators to advance and translate their research.

Award Amount: \$1.5 million paid over 5 years

Indirect Costs: Unspecified

Application Deadline: Feb 21, 2018

Website: <https://nyscf.org/programs/extramural-grants/applicants/stem-cell-investigator-awards/>

13. Research Grants, North American Spine Society (NASS)

NASS is a premier multidisciplinary medical organization with over 7,800 physician and affiliated healthcare members in 101 countries dedicated to fostering the highest quality ethical, value-based and evidence-based spine care through education, research and advocacy. NASS membership includes the following spine-related specialties: orthopedics, neurosurgery, physiatry, pain management, research and other disciplines, including allied health professionals.

NASS strives to be a leading force in promoting and supporting spine research. NASS supports basic, clinical and translational science performed with integrity. The goal is to improve quality spine care for patients and understanding of underlying disorders. One way NASS achieves these goals is by funding grants and fellowships.

NASS research grants provide funding for promising research projects by qualified investigators in the field of spine. Any spine-related proposal will be considered. Funds are for work to be performed or works in progress, not works already completed. NASS does not support research for independent manufacturers, industry development or personal business financial gain. NASS will be sensitive to this issue.

Research grants should focus on basic science, clinical or translational research. Basic research may focus on projects that further our understanding of the mechanisms of disease and developing novel models for prevention and/ or treatment. Clinical research may focus on projects that investigate the epidemiology, prevention, and or treatment of spine disease. Translational research may focus on projects that move findings from the 'bench to bedside'.

Award Amount: Up to \$50,000 for 1 year (\$20,000-\$40,000 recommended amount to request)

Indirect Costs: 15%

Preliminary Proposal Deadline: Feb 12, 2018

Website:

<https://www.spine.org/ResearchClinicalCare/ResearchGrantsFunding/FundingOpportunities.aspx>

14. Young Investigator Grants, North American Spine Society (NASS)

NASS is a premier multidisciplinary medical organization with over 7,800 physician and affiliated healthcare members in 101 countries dedicated to fostering the highest quality ethical, value-based and evidence-based spine care through education, research and advocacy. NASS membership includes the following spine-related specialties: orthopedics, neurosurgery, physiatry, pain management, research and other disciplines, including allied health professionals.

NASS strives to be a leading force in promoting and supporting spine research. NASS supports basic, clinical and translational science performed with integrity. The goal is to improve quality

spine care for patients and understanding of underlying disorders. One way NASS achieves these goals is by funding grants and fellowships.

NASS research grants provide funding for promising research projects by qualified investigators in the field of spine. Any spine-related proposal will be considered. Funds are for work to be performed or works in progress, not works already completed. NASS does not support research for independent manufacturers, industry development or personal business financial gain. NASS will be sensitive to this issue.

Research grants should focus on basic science, clinical or translational research. Basic research may focus on projects that further our understanding of the mechanisms of disease and developing novel models for prevention and/ or treatment. Clinical research may focus on projects that investigate the epidemiology, prevention, and or treatment of spine disease. Translational research may focus on projects that move findings from the 'bench to bedside'.

Award Amount: Up to \$50,000 for 1 year (\$20,000-\$40,000 recommended amount to request)

Indirect Costs: 15%

Preliminary Proposal Deadline: Feb 12, 2018

Website:

<https://www.spine.org/ResearchClinicalCare/ResearchGrantsFunding/FundingOpportunities.aspx>

15. SFARI Explorer Awards, Simons Foundation/Simons Foundation Autism Research Initiative (SFARI)

The mission of the Simons Foundation Autism Research Initiative (SFARI) is to improve the understanding, diagnosis and treatment of autism spectrum disorders (ASD) by funding innovative research of the highest quality and relevance.

To this end, the foundation solicits applications for SFARI Awards from individuals who will conduct bold, imaginative, rigorous and relevant research.

This award program is designed to enhance the foundation's existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. Proposals at all of these levels will be considered.

Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are encouraged. We especially encourage applications from investigators who

are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder.

Award Amount: \$80,000 for 1 year

Indirect Costs: 20%

Application Deadline: Continuous

Website: <https://sfari.org/funding/grants/explorer-awards-rfa>

16. Research Grant Program, The Glaucoma Foundation (TGF)

The Foundation offers grants to researchers striving to improve the lives of glaucoma patients through novel innovations and scientific advances. The area of current focus for TGF's Grant Research program is exfoliation syndrome and exfoliation glaucoma.

Award Amount: \$60,000 for 1 year

Indirect Costs: None

Application Deadline: Jan 5, 2018

Website: http://www.glaucomafoundation.org/Grant_Application.htm

17. Child Development, The Waterloo Foundation (TWF)

TWF is interested in the psychological and behavioural development of children's, and particularly in certain neurodevelopmental conditions and the factors that influence them. To that end the Foundation funds research, as a main priority. The Foundation also funds some non-research projects, including dissemination of research and to a lesser extent intervention projects.

Award Amount: £40,000- £60,000 GBP

Indirect Costs: None

Application Deadlines:

- Mar 4, 2018 Developmental Trauma and Sleep/Exercise topics
- Jul 1, 2018 Motor Impairments and Diet and/or Microbiome topics